Skip to main content
< Back to news
Josep Lluís Sanfeliu, from Asabys (centre), with Rafel Bru and Jordi Carrera, founders of DeepUll (Photo Deepull).

Sabadell Asabys invests in DeepUll extending its Series B to €17M

Asabys Partners announces today the first investment of its new fund, SAHII II (Sabadell Asabys Healthcare Innovation Investments II), launched with the support of Banco Sabadell, in DeepUll, a disruptive medical diagnostics company, based in the Barcelona Science Park, developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections. DeepUll was founded in 2020 at the Barcelona Science Park by the serial entrepreneurs in diagnostics, Jordi Carrera and Rafel Bru,

DeepUll raised €13 million Series B financing round in October 2022 from investors like Werfen, Innvierte (CDTI), Kurma Partners, Alta Life sciences, UI Investissement (advised by Mérieux Equity Partners) and Axis Participaciones Empresariales. The investment is devoted to the development of its first-in-class sepsis recognition platform, with the aim to drastically improve patient outcomes and reduce the unnecessary use of antimicrobials. SAHII II’s investment provides additional funding to the company, allowing them to continue the development of the technology and its path towards the market. DeepUll is the first investment of Asabys’ second fund, announced last week.

Josep Ll. Sanfeliu, founding and managing partner at Asabys joining the Board of DeepUll, comments: “DeepUll is the perfect example of a disruptive company in the diagnostic space, led by an outstanding team and using high advanced technologies to solve a clear unmet medical hospital need in the area of infectious diseases.”

Ramon Benet, Venture Partner at Asabys, has been instrumental in the analysis of the opportunity. Ramon has a long-time expertise in the In Vitro Diagnostics and Medical Device industries in Europe and in the US, with previous executive roles at Werfen and Instrumentation Laboratory in the US.

Jordi Carrera, chief executive officer and co-founder of DeepUll adds: “We are delighted to bring Asabys as a new investor to DeepUll. Asabys’ belief in health technologies and their expertise investing in life sciences innovation, add great value to the company, supporting our growth and helping us reach relevant milestones for the ultimate benefit of patients.”

» For further information: Asabys website [+]
» Related news [+]